Avant Begins Phase II Testing of Typhoid Fever Vaccine

Avant Immunotherapeutics announced the initiation of enrollment in a randomized, placebo-controlled, double-blind Phase II study of its typhoid fever vaccine candidate, Ty800, in approximately 180 healthy adult volunteers.

The Phase II study is an outpatient, dose-ranging clinical trial that will evaluate two dose levels of the single-dose, oral Ty800 vaccine and will follow each subject for six months post-vaccination, Avant said.

The objectives of this Phase II study are to determine the optimal dose of Ty800 for further development based on the safety, reactogenicity and immunogenicity of the vaccine, the company added.